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Multiple functional challenges in the use of pharmaceutical packaging reveal a great need of packaging 
to be designed inclusively. This study investigates patient involvement in the pharmaceutical packaging 
design process by analysing interview data from representatives of the pharmaceutical and packaging 
industry. Four main themes related to patient involvement were uncovered: patient expertise levels, 
patient involvement modes, factors encouraging patient involvement, and factors discouraging patient 
involvement. Passive patient involvement modes were found to be dominant due to regulations and a 
traditional perspective regarding physical testing. However, active patient involvement modes were 
identified, motivated by empathy and understanding of the lives of patients. The pharmaceutical 
packaging design process is complex and involves multiple stakeholders. The research findings can 
inspire more industry practitioners and policymakers to design pharmaceutical packaging that is 
inclusive and with consideration of a broader spectrum of patients’ needs. 
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INTRODUCTION
Industrial choices made in design processes 
account for the final uses of products (design for 
users) and reflect the way the industry itself per-
ceives and involves users in the design process 
(design with and by users) [1, 2]. For industries that 
are not traditionally user-oriented, it can be par-
ticularly challenging to be informed by user inputs 
during the design process. The pharmaceutical 
industry, associated with the packaging industry, is 
an example of an industry that is highly regulated 
and centred on science-based drug development [3], 
but an industry that has been challenged to deliver 
more inclusive and patient-centred alternatives to 
treatment and medication intake [4].
Inclusive design means that when designing 
products, one should take into consideration users 
with different skills and (dis)abilities – which makes 
sense when thinking about the different ways people 
are affected by a disease and the profound changes 
that can come to life during treatment. Regarding 
packaging, researchers have stressed the need for 
inclusive design in general [5, 6] and pharmaceuti-
cal packaging particular [7-13].
Despite its relevance, most of the previous 
research has focused on the functional difficul-
ties created by pharmaceutical packaging, without 
paying attention to the participation of patients in 
the design process [14]. Because of its complex mul-
tidisciplinary development, pharmaceutical pack-
aging usually relies on a design process conducted 
by what could be called a ‘design collective’ [15]. 
This means many important design decisions are 
often not even made by designers, but by people 
from business development, risk management, and 
manufacturing who lack training in how to involve 
users and address their needs by means of inclu-
sive and user-centred design processes. The same 
kind of design collective as well as limitations to 
user involvement is expected in pharmaceutical 
packaging design, where patient involvement has 
been under investigated.
Thus, this study aims to explore current industry 
practices of patient involvement when designing 
pharmaceutical packaging. The point of depar-
ture is that independent of the type of medication, 
a pharmaceutical package will only suit patients’ 
needs if those needs are understood by asking and 
letting the patients take part in the design process. 
This study considers both prescribed medica-
tions (those only sold or given to patients prescribed 
by physicians) and over-the-counter medications 
(OTCs, medication products that can be marketed 
and sold to patients without a physician’s prescrip-
tions). When it comes to packaging, we consider 
the primary packaging system level [16], which 
includes both the inner packaging (in direct contact 
with the medication, such as blisters, plastic bottles, 
glass vials) and outer packaging (that contains the 
inner packaging, such as a carton board box or 
wrapping). We do so because inner and outer pack-
aging are assessed together by regulatory boards 
and are viewed as a packaging system that protects 
and delivers the medication used by patients.
DESIGNING INCLUSIVE PHARMA-
CEUTICAL PACKAGING: FROM 
MEDICALISATION TO EMPOWERED 
SELF-CARE
Inclusive approaches, such as universal design 
[17], inclusive design [18], and design for all [19], 
have motivated a new design methodology involving 
highlighting who would be able to use the products 
of interest and who would be excluded from using 
them because of their design [20]. Each of these 
inclusive approaches started at a different point 
in time and place, but they have a common goal 
of integrating the mainstream and subsets of the 
population (e.g., people with disabilities and older 
people) into the design process. However, inclusive 
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design approaches in practice often struggle to 
reach their main goals, either because it is demand-
ing to change policies or because there are budget 
limitations, time constraints, and an overall lack of 
perception of the needs of different users [21]. 
Inclusive approaches to design call for atten-
tion to the level of user involvement. A predominant 
and traditional view of user involvement empha-
sises the ‘expert view’, where an expert is trained to 
observe and/or interview a selected group of users 
who perform different pre-delimited tasks, test pro-
totypes, or simulate interaction scenarios [22]. As 
a result, users are a source of information, with 
passive involvement in the design process [23]. Con-
versely, a participatory approach unites the worlds 
of the user and designer and offers more creative and 
empathic design process techniques [24]. Currently, 
a participatory approach is often referred to as co-
design, which means ‘the creativity of designers 
and people not trained in design working together in 
the design development process’ [22]. By participat-
ing and being involved, users are invited not only 
to perform pre-defined tasks or test already-made 
prototypes in the design process, but also to co-
create and elaborate on concepts via enriched and 
hybrid forms of collaboration [25]. 
The call for user participation in design is not 
new [26]. However, it has only been in recent years 
that researchers have begun to show a growing 
interest in the experiences of patients as users of 
products and services that are essential for their care 
and directly affect their emotions and well-being 
[27, 28]. The increasing focus on patients is linked 
to important social and demographic changes, par-
ticularly those pertaining to ageing, with people 
living longer with chronic conditions and taking 
multiple medications every day [29]. The expansion 
of medication usage, referred as ‘medicalisation’ 
[30], draws attention to patients’ in managing their 
own care and their agency in taking or not taking 
their medication [31].
How patients integrate a treatment into their 
lifestyle can determine its success. In that sense, 
the pharmaceutical industry constitutes a singular 
business case in which an inclusive design approach 
is necessary to come up with pharmaceutical pack-
aging that can be used by a broad spectrum of 
patients [32]. To motivate the correct intake of med-
ication and adherent behaviour by patients, health-
care agencies and policymakers have called for 
innovative solutions that can empower patients and 
make them more active in caring for themselves, 
especially in the long-term perspective [33]. This 
fuels the demand for well-designed medication 
products and tools [34]. 
A way forward to more inclusive pharmaceu-
tical packaging is to involve patients in the design 
process. This study looks closer to industry prac-
tices in place for patient involvement and to the 
level of patient involvement in connection to the dif-
ferent phases of the existing design process.
METHODOLOGY
This research intends to answer two research 
questions:
• How are patients involved in the pharmaceuti-
cal packaging design process?
• What encourages or discourages patient 
involvement in the pharmaceutical packaging 
design process?
With these research questions as guidance, 
we opted to conduct semi-structured interviews 
with professionals who had experienced patient 
involvement in the pharmaceutical packaging 
design process. This was supported by a qualita-
tive research approach [35], in which qualitative 
interviews were performed to gain ‘in-depth infor-
mation pertaining to participants’ experiences and 
viewpoints of a particular topic’ [36]. By doing 
that, researchers have the chance to learn from 
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Table 1. Respondent characteristics
response saturation was achieved [39]. The organ-
isations where respondents worked have an inter-
national profile, with products attending a range 
of markets across the globe, but mostly focused on 
the European and North American markets. One 
company is based in Asia. Table 1 presents the 25 
respondents in the study.
Data collection
An interview script was prepared with open-
ended and discovery-oriented questions, includ-
ing questions about patient involvement and par-
ticipation in designing pharmaceutical packaging. 
In addition to that, other relevant questions were 
added about the holistic process of pharmaceutical 
accumulated experiences that they could not expe-
rience themselves and give the respondents the 
opportunity to reflect on their own practices.
Respondent selection
The initial respondents were selected via pur-
poseful sampling [37], based on their past experi-
ences with pharmaceutical packaging design and 
their many years of work experience within the 
pharmaceutical and/or packaging industry. Addi-
tional respondents were added through respondent-
driven sampling [38], allowing access to other-
wise hard-to-reach respondents within the same or 
related organisations. As recommended by the liter-
ature, we stopped reaching out to respondents when 
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Table 1. Respondent characteristics, continued
innovation and the packaging design process. 
Over an eight-month-long period, one individual 
interview was conducted with each respondent, with 
durations ranging from 25 min to 2 h and 17 min, with 
an average of 1 h and 14 min. Face-to-face interviews 
were preferred, although telephone interviews were 
conducted due to geographic constraints in 10 of the 
25 cases. Each interview was preceded by obtaining 
informed consent, and all of the respondents agreed to 
the audio recording of their conversations. Subsequent 
follow-ups were conducted via electronic communica-
tion and telephone calls for clarification.
Data analysis
All of the audio recordings were transcribed 
verbatim. Departing from the original research 
questions, we began by adapting the main steps of a 
general inductive approach for analysing qualitative 
data [40], which consisted in the following phases: 
Phase 0 – Preparation of raw data files and export to 
qualitative data analysis software (NVivo, QSRIn-
ternational); Phase 1 – Close reading of the inter-
view data andinitial themes; Phase 2 – Creation of 
a theme scheme; Phase 3 – Refinement of the coded 
and uncoded text; Phase 4 – Assessment of trust-
worthiness. Figure 1 summarises the data analysis 
process.
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Figure 1. Data analysis process
Table 2. Final coding scheme
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By successive re-reading of the raw data, 
relevant segments of text were classified according 
to the initial unstructured themes and subthemes 
until four main themes clearly emerged by the 
end: patient expertise levels, patient involvement 
modes, factors encouraging patient involvement, 
and factors discouraging patient involvement. Table 
2 presents the final coding scheme.
ANALYSIS OF KEY FINDINGS
In the following sections, we present and 
analyse the key findings that emerged from the 
interviews. Selected quotations illustrate how the 
respondents expressed themselves and synthe-
sise some of the key findings. Minor edits of the 
quotations, enclosed in brackets, were made to 
facilitate comprehension – for instance, pauses or 
broken sentences were removed.
Patient expertise levels
Users have different expertise levels depending 
on their previous product usage [41]. We identified 
respondents were concerned with the patients’ level 
of expertise and patients’ awareness and acceptance 
of their own health conditions. Figure 2 illustrates 
the three patient expertise levels emerged from the 
interview data: pre-patient, experienced patient, 
and patient advocate.
Pre-patient
A pre-patient is considered a naïve patient who 
has just become aware of the disease or condition. 
Figure 2. Patient expertise levels
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In this sense, a pre-patient is also a future user of 
the medication. Commonly, pre-patients refuse 
or postpone the beginning of treatment [34]. Pre-
patients often have high stress levels because they 
need to learn how to navigate their illnesses. The 
respondents perceived that packaging has a specific 
role in helping these patients to find guidance and 
instruction to carry out their treatment correctly. 
Independent of the disease, pre-patients are more 
likely to make mistakes or use the packaging in 
unexpected ways, which can help packaging teams 
uncover unexpected packaging use.
Experienced patient
Experienced patients are those patients who 
have lived with one or more diseases for a long 
time. They have tacit knowledge, which means they 
‘have in mind a pattern born of experience, which 
they can overlay on a particular problem and use to 
quickly detect a solution’ [48]. Experienced patients 
are often of the greatest interest to packaging design 
teams, as those patients have extensive experience 
living with certain conditions and have developed 
their own strategies to cope with both their condi-
tion and the functional challenges that they might 
face with the medication and its packaging.
Patient advocate 
The third level is the patient advocate level. In 
the literature, a closely related concept would be the 
‘lead user’ [2]. Lead users combine expertise in the 
context of usage with the eagerness to innovate and 
perform product design changes. However, we could 
not identify patients as lead users in our interview 
data, as the patients were never mentioned as the 
initiators of pharmaceutical packaging innovations. 
Therefore, a more appropriate concept is ‘patient 
advocate’: a person who assumes the responsibil-
ity of advocating and talking about the needs of a 
whole group of users, as defined by [49]. 
Typically, patient advocates are members of 
patient associations, a network of patients engaged 
in their diseases, treatment, and quality-of-life 
improvement. Patient advocates are considered to 
be extremely involved in their diseases, which may 
demand caution from packaging teams, as not all 
patients will be as engaged as these patients.
Patient involvement modes
Arnstein [26] described a taxonomy of user 
involvement ranging from non-participation to 
tokenism and then citizen power. Similarly, Damo-
daran [44] defined three user involvement levels: 
informative (user provides information and pas-
sively helps generate data), consultative (user 
comments on pre-defined concepts or prototypes), 
and participative (user actively influences deci-
sions). Kaulio [1] proposed another scale in which 
the design process is conducted for, with, or by 
users. In general, the prevalent idea behind these 
similar classifications is that user involvement will 
vary from passive to active, depending on when 
and how users enter the design process and to what 
extent they are allowed to influence it. Inspired by 
the literature on user involvement, our iterative 
coding process led us to identify and synthesise six 
patient involvement modes, presented in Table 3.
Ethnography
Respondents mentioned ethnography as one 
mode of patient involvement to discover the ‘world 
of the patient’. Hence, ethnography worked as 
a sort of inspiration for defining patient needs, 
understanding the lives of patients, and identify-
ing ‘exactly how our products will live with the 
patients’ (D12). Anthropologists at the company, or 
hired by the company, would travel across the globe 
to meet patients at their homes to observe the use of 
the medication and packaging in real-life situations.
They [the anthropologists] got permission 
to follow a patient a whole day to see how 
he managed, administrated his medication. 
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Table 3. Patient involvement modes and levels
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Where he [the patient] started, how he used 
it, and just looking at him, and following him 
the whole day. And that gives extremely good 
information for us to see where the hurdles 
are for him [the patient]. (D5)
The respondents also commented that ethnog-
raphy is used to add stimuli to the reality of the 
patients, especially when testing preliminary pack-
aging design concepts with a group of patients with 
one specific disease.
Talks by patients
Respondents commented that they had attended 
talks given by patients. These talks were arranged 
as very explorative and inspirational seminars at the 
companies’ premises, where patients talked with 
staff from different departments about the reality of 
being a patient and living with a disease.
We invite them here for seminars, we invite 
them to talk about their lives, you know. So, 
it’s extremely important that we understand 
them thoroughly. (D1)
The talks permitted the patients to frame and 
phrase their realities, instead of having someone 
observe them. D6 commented that patients ‘[...] 
come and tell about the experience of having the 
disease, and how they perceive the products and the 
challenges’. For D5, the meetings with the patients 
focused on exploring ‘what is a daily life for you 
with this disease?’, rather than asking patients to 
assess specific medication or package.
Co-creation workshops
Another means of involving patients early in the 
development of new packaging designs is via co-cre-
ation workshops, during which the packaging design 
team and selected patients interact to develop new 
packaging concepts together and iteratively.
We have gone off-site for a couple of days, 
and we’ve had different patients in and we 
had interview sessions, where essentially I 
conducted an interview with a patient for an 
hour, and then ten engineers would sit and 
listen to the patient, how they live, what their-
problems are, and then go away for an hour, 
and come back with three different concepts 
to improve their life, just the ideas, an app, a 
device, or anything it could be. (D12)
At these sessions, the patients worked with 
sketches or very rough mock-ups to visualise future 
packaging concepts, not necessarily connected to 
one new specific medication but related to a disease 
or condition patients had in common.
So, we asked some people to do some 
drawings, for example, people said ‘Ok, it 
should look like this’. And someone drew 
it, ‘Yeah, but you need to be able to put it 
in your pocket and in your purse’, you know, 
it should be small. So, we started with a 
problem, you know, and we tried to see how 
they would like to solve that. (D1)
Rapid prototyping and visualisation workshops
A common practice highlighted by the respon-
dents is the presentation of rapid prototypes and 
visualisation workshops with patients (Figure 3). 
The prototypes were usually developed by in-house 
3D printers or by packaging suppliers. As specifi-
cally commented by P4, workshops with rapid pro-
totypes permitted designers and engineers to show 
patients possible solutions in one or more visual and 
tridimensional artefact, which could be helpful to 
start an in-depth discussion.
Usability testing
Several respondents commented on their expe-
riences with or awareness of usability tests, per-
formed according to strict documentation and 
standard protocols. For pharmaceutical manufac-
turers, usability testing is an obligatory phase for 
certain packages (e.g., child-resistant packages), 
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during which the packaging design is validated. 
Regularly, the usability tests were filmed, and 
patients were asked to make comments during their 
interactions with the packaging.
You put the system in the hand of the patient, 
and they have to operate the system. And the 
company has to document that the patient is 
able to use it. That they don’t do dangerous 
mistakes and so on. So that is perhaps the 
most important feedback mechanism during 
development. (D6)
Formal patient feedback
Formal patient feedback was also mentioned 
by the respondents. Any formal feedback about 
the packaging reported by patients to the ombuds-
man service at the pharmaceutical manufacturer 
requires the packaging teams’ attention, which has 
to analyse and discuss improvements. This situation 
is rare according to the respondents and should be 
prevented. There is also informal feedback about 
the packaging, which is gathered by sales people 
or marketing teams. Informal feedback does not 
require immediate responses from pharmaceuti-
cal manufacturers but serves to provide insights for 
future development.
[...] so, we will take all the complaints, work 
why patients were complaining about it and 
then make some proposed changes to the 
pack. And again, just test those within a 
small number of people and see what they 
say. And hopefully launch a better pack, a 
new improved pack. (D10)
Factors encouraging patient involvement
By involving users, designers benefit from 
feedback at multiple phases and simultaneously 
create solutions that satisfy user needs [47]. In 
this research, patient involvement was found to be 
important when the packaging is a critical part of 
the treatment and a potential hazard causing failure 
and severe mistakes. Three subthemes emerged and 
are detailed in the following.
Understanding actual usage
Respondents are encouraged to involve patients 
to learn and understand the realities of drug product 
usage, especially during discovery-oriented stages 
of packaging design. Identifying the differences 
between the intended and actual usage is one of the 
major benefits of patient involvement in the pack-
aging design process for pharmaceutical products:
The user [patient] might think something is 
good and it’seasy to use, but if you observe 
how they use it, they might use it wrong, 
or they might have difficulty using it, even 
though they say they think it’s easy. [...] How 
they actually use it, not how they think they 
use it. (D12)
So actually, we observe to see if they don’t 
use it as we intended, so from my point of 
view, it’s very important that the designer 
that designed this box is observing instead of 
reading a report afterwards. (D11)
In another example, a participant told a short 
anecdotal story about facing the struggle of a patient 
with a package.
Figure 3. Examples of rapid prototypes tested by 
patients. Source: Respondent P3
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There was a patient here, in a big meeting, 
and she was enthusiastic, and she said ‘this 
is a fantastic product, it helps me very, very 
much’, and she showed the [package] and she 
said ‘well, it’s very hard to get it out, because 
you have to press out this [name] product out 
of the [package], and I have arthritis also in 
my hands. I have a trick’. And she said ‘I take 
a plastic bag and I put the [package] on that, 
and then I press it with my foot, and then I 
take it out and use it, and it works fine’, she 
said. And it was really embarrassing hearing 
this, you know. (D1)
In this situation, the personnel involved with the 
medication project at the company had the opportu-
nity to meet the patient to hear about her experi-
ence with the medical product. However, it turned 
out that the packaging was at the centre of atten-
tion. The unexpected method of getting the product 
out of the package provided the design team with 
insights about the packaging design.
Creating empathy with patients
Eagerness to empathise with patients was men-
tioned as an encouraging factor. Importantly, some 
of the respondents referred to empathy with patients 
as part of the organisational culture shared among 
the employees at the company level and extending 
beyond the packaging team.
I saw a presentation of somebody [...] and 
one of his keywords was not designed for 
the patient, for the user, but with the user. 
He could show he changed the design of an 
injectable design packaging for RA [rheu-
matoid arthritis], with patients’ involvement. 
(A2)
Meeting the patients was also an opportunity to 
be ‘challenged by somebody who actually has this 
everyday use and be surprised by what their per-
ception is compared to your perception of reality’ 
(D11). By creating empathy with the patients, the 
packaging teams could elaborate on future solu-
tions to facilitate medication intake and improve 
adherence rates.
Compliance with regulations
Our data show that patient involvement in pack-
aging development is strongly influenced by the 
specific policies and regulations, which vary across 
different markets. It is the responsibility of phar-
maceutical manufacturers to comply with regula-
tions; however, packaging suppliers are also moti-
vated to perform user tests to fulfil the regulations 
and queries of their customers (i.e., pharmaceutical 
manufacturers). For instance, one important piece 
of legislation mentioned is the Poison Prevention 
Packaging Act of 1970 (PPPA) for the US market 
[50], which requires child-resistant packaging for 
several household packages, including prescribed 
medication and over-the-counter products.
Factors discouraging patient involvement
We identified three factors that were particu-
larly challenging according to respondents: who 
to involve and when to involve them, the available 
resources, and what is allowed.
Who to involve and when to involve them
Active and participatory involvement should 
start early in the development process. Our data 
revealed that it was difficult to define the right point 
of patient involvement. For instance, P2 commented 
that the company is global, which makes it difficult 
to select and work with local patient organisations 
in patient recruitment. Another respondent (M2) 
commented that interacting with patients in early 
phases without having a concept to discuss can be 
misguiding and impractical. On the other hand, 
bringing ‘something that looks like a final product’ 
(M2) is also not positive, as time would have passed 
in developing something that patients may dislike. 
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Additionally, patients living with a certain chronic 
condition are not always a homogeneous group, 
with a variety in their level of expertise as well. 
Available resources
Another discouraging factor includes the opera-
tionalisation of patient involvement, such as budget, 
time, and extensive documentation. The develop-
ment of a new medication takes many years and 
is a high-cost investment, which means packaging 
needs to be seen as a critical element for the medica-
tion project. For instance, this happens when a new 
medication requires additional protection or pack-
aging features that cannot be supplied by a packag-
ing that has been previously developed. Otherwise, 
pharmaceutical manufacturers will more likely use 
the packages already in their portfolio to decrease 
development costs and increase speed to market.
Moreover, developing inclusive packaging 
focused on patients’ needs is embedded in the 
culture of some major pharmaceutical manufac-
turers, but it is not the priority for all companies 
involved with the packaging design process, as 
stated by one respondent:
Many don’t have the resources, don’t have 
the leadership who demands this to happen. 
You can have companies very, very active, 
pro-active, and others are not, it’s not part of 
their genes. (A2)
What is allowed
Most of the activities that involve patients need 
to be performed by consultancies or third parties 
outside the facilities of a company, which requires 
ethical considerations. As commented, ‘pharmaceu-
tical companies, they want to get patients involved 
but they have legal restrictions in their communica-
tion with patients that makes it difficult’ (A1). For 
medications that are planned to be sold globally, 
there is an additional complication of dealing with 
different regulatory boards and guidelines that 
restrict patient involvement for major and global 
medication projects where many market opportuni-
ties are foreseen.
‘cause it is quite a big investment to run a 
usability study, it takes time and it is a little 
bit complicated for the industry to interface 
and compensate the test participants for their 
time, and there is a lot of regulations on that, 
so it is important that we get good output for 
the pack. (M2)
DISCUSSION
Pharmaceutical packaging can put patients at 
risk when different design aspects are not consid-
ered [13]. As expected, one main factor encourag-
ing patient involvement is proof that the packag-
ing is safe for use and complies with the relevant 
policies and regulations. Therefore, it is impera-
tive to understand the actual use of packaging by 
involving patients in situations that mimic their 
reality of medication usage. This motivation found 
in our results is not distant from what the litera-
ture suggests about involving users in design pro-
cesses to achieve understanding of the context of 
use, getting access to first-hand knowledge about 
the contexts in which products are used [51].
Luck [52] affirmed that ‘the social process 
of participatory design and design dialogue has 
enabled the transfer of user knowledge to design-
ers who may be able to use this knowledge for the 
users’ benefit’. However, it is not easy to transport 
the ideals of inclusive design into practice without 
the creation of user stereotypes and common dis-
abilities [53, 54]. We found that stereotypes could 
be deconstructed when patients had the opportunity 
to share their stories. The talks given by patients 
provided an open environment for these patients to 
discuss what was important to them. As supported 
by previous research [55], patients sometimes 
showed creativity and a strong will to circumvent 
Listening to Current Practice: Patient Involvement in the Pharmaceutical Packaging Design Process 
difficulties to succeed in their treatment, surprising 
the professionals responsible for packaging devel-
opment.
The discouragement factors for patient involve-
ment identified relate to those already found by the 
literature [21]. These factors seemed to be stressed 
even more in the pharmaceutical packaging context 
as this is a highly regulated business with signifi-
cant differences across countries, where forceful 
regulatory bodies control medication and packag-
ing development to ensure patient safety [56]. The-
regulatory differences among borders create a dif-
ficult scenario for pharmaceutical companies, as 
one new packaging does not fit all the company’s 
markets. This can make it particularly difficult to 
achieve the ideals of inclusive design, where pack-
aging is intended to be designed for abroader range 
of the population but framed by regulations that 
impose different demands on the design process, 
and directly affect how a final package may look 
like. In practice, this means changing a packag-
ing already launched will only be done when abso-
lutely necessary, and not always motivated by the 
needs expressed by patients. Packages already 
launched tend to remain in the company’s portfo-
lio – and that explains why many pharmaceutical 
packaging designs that are functionally challeng-
ing to patients continue to be produced for decades 
[14]. Conversely, an opportunity arises when a new 
medication is under development with a need for 
a new packaging – in those cases, having patients 
involved in the design process seems to be particu-
larly valuable to the creation of packaging that fits 
with patients’ needs.
One interesting aspect was the level of exper-
tise of the patients involved. Scholars have reported 
that user participation is often realised with the pro-
fessionalisation of public participants [57]. This 
feature was partly identified in this study, as patients 
engaged in patient associations were a recurrent 
source of knowledge for the packaging teams. 
Experienced patients were repeatedly included, 
although patients with little or no experience were 
also involved, as different ranges of experience 
expanded the understanding of usage. However, it is 
important to consider that patients might also lack 
a systematic view of all the complexities that are 
embedded in pharmaceutical packaging develop-
ment, from regulatory constraints to intricate supply 
chains around the globe. Even though we could 
identify many efforts made to involve patients, and 
a great interest of the professionals inlistening to 
patients’ experiences, limitations on how the phar-
maceutical business model is established make it 
challenging to have patient involvement that goes 
beyond informative and/or consultative roles or to 
pursuit packaging that is designed for inclusivity. 
Inclusive pharmaceutical packaging remains as an 
exception – a view to be challenged by the efforts of 
many different actors, from patient associations to 
regulatory bodies and other decision-makers.
CONCLUSION
This research has investigated industry prac-
tices of patient involvement for inclusive pharma-
ceutical packaging design. By asking: ‘How are 
patients involved in the pharmaceutical packaging 
design process?’, we explored the patient involve-
ment modes and levels and the extent to which the 
professionals working with packaging design and 
patients in fact work together in the design process. 
Our findings revealed:
• Six modes of patient involvement were identi-
fied (ethnography, talks by patients, co-creation 
workshops, rapid prototyping and visualisation 
workshops, usability testing, and formal patient 
feedback) at different phases of packaging 
design process.
• The level of patient involvement was mainly 
informative or consultative, where patients 
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were asked to give their input on packaging 
concepts during development or to share their 
experiences of living with a disease or chronic 
condition.
• Long-term and in-depth patient involvement 
(e.g., ethnography) was limited in comparison 
to shorter and punctual mode of patient involve-
ment.
We also asked: ‘What encourages or discour-
ages patient involvement in the pharmaceuti-
cal packaging design process?’ The encouraging 
factors were:
• Understanding and comparing intended and 
actual usage of the medication and its pack-
aging, by adding stimuli to the world of the 
patients. 
• Creating empathy with patients to better under-
stand their needs and the reality (and complex-
ity) of being a patient.
• Compliance with regulations as a ‘must-do’, as 
packaging and medication need to be approved 
together at the end.
Conversely, discouraging factors were:
• Difficulty in knowing which patients to involve 
and when to involve them in the pharmaceutical 
packaging design process.
• Restricted availability of resources (time, 
budget for packaging design, human resources) 
to conduct studies with patients, combined with 
the view of packaging as an additional cost to 
the medication project.
• Long approval process in a highly regulated 
industrial context that add complexity to devel-
opment, reducing the speed to market for the 
medication.
Overall, our study has stressed the singulari-
ties of designing for patients and with patients. 
Patient involvement is one part of the challenges of 
having more inclusive pharmaceutical packaging, 
because without involving patients or by involving 
them only passively, their actual needs cannot be 
fully addressed. By affecting the lives of millions 
of patients, the pharmaceutical industry can benefit 
from a vision of inclusion and participation in its 
design processes.
A research agenda can explore other complex 
themes related to designing inclusive pharmaceu-
tical packaging in connection with major societal 
challenges. We suggest two themes related to this 
study that can be further explored:
• The extensive use of medication packaging and 
self-care: limited research exists presenting the 
routines and strategies followed by patients in 
their use of medication packaging in daily life. 
Studies in this area can apply different methods 
to gain insights about the complexities lived by 
patients, such as older patients, in their medica-
tion management.
• Methods for implementing gained insights into 
industrial design processes and for decision-
making for inclusive design of pharmaceuti-
cal packaging: a path forward is to observe 
and research closely how packaging design 
teams work to manage and implement insights 
from patients in new or improved packaging 
concepts, and how decisions are made impact-
ing on the packaging design.
Listening to Current Practice: Patient Involvement in the Pharmaceutical Packaging Design Process 
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